Casein Kinase
Casein Kinases (CKs), a group of ubiquitous Ser/Thr kinases, regulate a wide range of cellular functions in eukaryotes, including phosphorylation of proteins that are substrates for degradation via the ubiquitin-proteasome system (UPS). Two casein kinases, casein kinase-1 (CK-1) and casein kinase-2 (CK-2), have been characterized from many sources.
CK1 kinases exist in at least seven isoforms (α, β, γ1-3, δ, and ɛ) in mammals and CK1 kinases phosphorylate various substrates to play vital roles in diverse physiological processes such as DNA repair, cell cycle progression, cytokinesis, differentiation, and apoptosis. Casein kinase 2 (CK2) is a highly pleiotropic serine-threonine kinase, which catalyzed phosphorylation of more than 300 proteins that are implicated in regulation of many cellular functions, such as signal transduction, transcriptional control, apoptosis, and the cell cycle.
Casein Kinase Isoform Specific Products
All Product Categories
-
Casein Kinase Inhibitors
(201)
View all products
-
Casein Kinase Antagonists
(2)
View all products
-
Casein Kinase Activator
(1)
View all products
-
Casein Kinase Chemical
(1)
View all products
-
Casein Kinase Degraders
(23)
View all products
-
Casein Kinase Substrate
(1)
View all products
-
Casein Kinase Ligand
(1)
View all products
-
Casein Kinase Related Products (247)
Related Products (247)
-
Antibodies (5)
-
Casein Kinase Isoform Comparison
-
CK1α-IN-1
0 ImagesCat. No.: HY-181048CK1α-IN-1 (Compound 7a) is a selective CK1α inhibitor with an IC50 of 10.96 nM. CK1α-IN-1 dose-dependently stabilizes p53 protein. CK1α-IN-1 has anticancer activity against acute monocytic leukemia.
-
EGFR-IN-57
0 ImagesCat. No.: HY-146138CAS No.: 2492382-37-1EGFR-IN-57 (Compound 25a) is a potent, orally active EGFR-TK inhibitor with an IC50 of 0.054 µM. EGFR-IN-57 also inhibits VEGFR-2, CK2α, topoisomerase IIβ and tubulin polymerization with IC50 values of 0.087, 0.171, 0.13 and 3.61 µM, respectively. EGFR-IN-57 induces cell cycle arrest at G2/M and pre-G1 phases. EGFR-IN-57 induces cancer cell apoptosis.
-
Casein kinase 1δ-IN-15
0 ImagesCat. No.: HY-162336CAS No.: 2765264-27-3Casein kinase 1δ-IN-15 is an inhibitor for casein kinase 1 (CK1δ), with an IC50 of 0.045 μM.
-
SR-2890
0 ImagesCat. No.: HY-123859CAS No.: 1454584-91-8SR-2890 is a highly selective, ATP-competitive inhibitor of casein kinase CK1δ and CK1ε, with IC50 values of 4 nM and 44 nM, respectively, and a Ki of 14 nM for CK1δ. SR-2890 exhibits antiproliferative effects. SR-2890 blocks the serine/threonine kinase activity of CK1δ and weakly inhibits a few off-target kinases such as FLT3, CDK4. SR-2890 has an oral bioavailability of 10% and a blood-brain barrier penetration rate of <1%. SR-2890 demonstrates stable in vitro metabolism and favorable in vivo pharmacokinetic properties, effectively inhibiting the growth of human A375 melanoma cells. SR-2890 can be used in melanoma research and is also a useful compound for studying CK1δ/ε-related diseases such as Alzheimer's disease.
-
CSNK2A-IN-2
0 ImagesCat. No.: HY-163182CAS No.: 3029550-17-9
-
Levobunolol
0 ImagesCat. No.: HY-B1035ACAS No.: 47141-42-4Synonyms: l-BunololLevobunolol (l-Bunolol) is a non-selective β-adrenergic antagonist and vasodilator. By blocking calcium ion influx and reducing the sensitivity of vascular smooth muscle to calcium, Levobunolol effectively dilates the ciliary arteries and increases ocular blood flow, so it is widely used in research on glaucoma and ocular hypertension. Levobunolol inhibits the β-receptor signaling pathway and the expression of related proliferation markers (such as CK3, CK14, CK19, Ki67) in corneal cells. In rabbit models, Levobunolol not only does not inhibit corneal epithelial regeneration, but also accelerates the healing of mechanical injury without adverse effects. Levobunolol also inhibits histamine-induced vasoconstriction and intracellular calcium elevation, exhibiting unique vascular regulatory activity. Levobunolol protects ocular blood flow and promotes corneal repair.
-
CHX-3107
0 ImagesCat. No.: HY-105222ACAS No.: 127061-56-7CHX-3107 is a casein kinase 2 inhibitor .
-
Casein Kinase Substrates 3
0 ImagesCat. No.: HY-P1909CAS No.: 154444-97-0Casein Kinase Substrates 3 is a substrate of casein kinase.
-
Casein kinase 1δ-IN-19
0 ImagesCat. No.: HY-169689CAS No.: 782452-74-8Casein kinase 1δ-IN-19 (compound 492) is a potent casein kinase 1δ inhibitor. Casein kinase 1δ-IN-19 can be used in the study of neurodegenerative diseases such as Alzheimer's disease.
-
CCK1-specific peptide substrate
0 ImagesCat. No.: HY-P5526CCK1-specific peptide substrate is a biological active peptide. (This peptide sequence is based on rabbit muscle glycogen synthase with Ser7 phosphorylated. It is a peptide substrate for Casein Kinase I (CK1). CK1 phosphorylates Ser10. Ser7 is phosphorylated by PKA in vivo.)
-
WAY-606344
0 ImagesCat. No.: HY-169668CAS No.: 380423-28-9WAY-606344 (Compound 97) is a Casein kinase 1δ inhibitor. WAY-606344 is promising for research of Alzheimer's disease.
-
MI-2-80
0 ImagesCat. No.: HY-175600CAS No.: 1010099-35-0MI-2-80 is a molecular glue degrader. MI-2-80 induces proteins (such as IKZF1/3 and CSNK1A1) to bind to CRBN, promoting their ubiquitination and degradation.
-
Multi-kinase-IN-6
0 ImagesCat. No.: HY-156470CAS No.: 3009081-73-3Multi-kinase-IN-6 (compound 10e) is a multikinase inhibitor that shows good enzyme inhibitory activity against TrkA, ALK2, c-KIT, EGFR, PIM1, CK2α, CHK1, and CDK2. Multi-kinase-IN-6 reveals antiproliferative activity against MCF7, HCT116 and EKVX with IC50 values of 3.36 μM, 1.40 μM and 3.49 μM, respectively. Multi-kinase-IN-6 shows cell cycle arrest at the G1/S phase and G1 phase in MCF7 and HCT116 cells with good apoptotic effect.
-
Casein kinase 1δ-IN-5
0 ImagesCat. No.: HY-153904CAS No.: 1579991-10-8Casein kinase 1δ-IN-5 is a potent and selective protein kinase CK-1δ inhibitor with an IC50 of 47 nM. Casein kinase 1δ-IN-5 shows neuroprotective and anti-inflammatory properties both in vitro. Casein kinase 1δ-IN-5 has the potential for neurodegenerative diseases research.
-
HS-276 formic
0 ImagesCat. No.: HY-147141BHS-276 formic is an orally active, potent and highly selective TAK1 inhibitor, with a Ki of 2.5 nM. HS-276 formic shows significant inhibition of TAK1, CLK2, GCK, ULK2, MAP4K5, IRAK1, NUAK, CSNK1G2, CAMKKβ-1, and MLK1, with IC50 values of 8.25, 29, 33, 63, 125, 264, 270, 810, 1280, and 5585 nM, respectively. HS-276 formic reduces the expression of TNF, IL-6, and IL-1β. HS-276 formic can be used for rheumatoid arthritis (RA) research.
-
Casein kinase 1δ-IN-17
0 ImagesCat. No.: HY-169574CAS No.: 450394-66-8Casein kinase 1δ-IN-17 (compound 753) is a casein kinase 1δ (CK1δ) inhibitor. Casein kinase 1δ-IN-17 can be utilized in neurodegenerative disorders research.
-
CK2-IN-7
0 ImagesCat. No.: HY-153788CAS No.: 2825012-70-0CK2-IN-7 (compound 2) is an inhibitor of casein kinase 2 (CK2). CK2-IN-7 shows synergistic effect with structurally distinct CK2 chemical probe: SGC-CK2-1, against cancer.
-
Casein kinase 1δ-IN-22
0 ImagesCat. No.: HY-169701CAS No.: 756849-12-4Casein kinase 1δ-IN-22 (compound 484) is a potent casein kinase 1δ inhibitor. Casein kinase 1δ-IN-22 can be used in the study of neurodegenerative diseases such as Alzheimer's disease.
-
Casein kinase 1δ-IN-18
0 ImagesCat. No.: HY-169577CAS No.: 522626-08-0Casein kinase 1δ-IN-18 (compound 660) is a casein kinase 1δ (CK1δ) inhibitor. Casein kinase 1δ-IN-18 can be utilized in neurodegenerative disorders research.
